Analyst Ratings for [BOLD] Audentes Therapeutics, Inc.

12/13/24	Downgrades	Buy Neutral	X
BOLD Boundless Bio Guggenheim
4/22/24	Initiated	Buy	X
BOLD Boundless Bio Guggenheim
$24
4/22/24	Initiated	Outperform	X
BOLD Boundless Bio Leerink Partners
$25
4/22/24	Initiated	Overweight	X
BOLD Boundless Bio Piper Sandler
$20
4/26/19	Downgrades	Neutral Sell	X
BOLD Audentes Therapeutics Citigroup
$28 $32
4/26/19	Reiterated	Buy	X
BOLD Audentes Therapeutics H.C. Wainwright
$44 $48
2/25/19	Upgrades	Neutral Buy	X
BOLD Audentes Therapeutics Chardan Capital Markets
$35 $40
1/11/19	Upgrades	Neutral Buy	X
BOLD Audentes Therapeutics Guggenheim
11/26/18	Initiated	Overweight	X
BOLD Audentes Therapeutics JP Morgan
$35
11/7/18	Reiterated	Sell	X
BOLD Audentes Therapeutics B. Riley FBR
$20 $21
11/7/18	Downgrades	Outperform Mkt Perform	X
BOLD Audentes Therapeutics William Blair
10/12/18	Reiterated	Buy	X
BOLD Audentes Therapeutics H.C. Wainwright
$33 $29
10/10/18	Initiated	Neutral	X
BOLD Audentes Therapeutics Guggenheim
9/7/18	Initiated	Sell	X
BOLD Audentes Therapeutics B. Riley FBR
$20
9/7/18	Initiated	Sell	X
BOLD Audentes Therapeutics Cowen
$20
8/21/18	Initiated	Neutral	X
BOLD Audentes Therapeutics Citigroup
$40
6/26/18	Initiated	Neutral	X
BOLD Audentes Therapeutics Chardan Capital Markets
$35
2/13/18	Initiated	Neutral	X
BOLD Audentes Therapeutics Mizuho
$26

BOLD Audentes Therapeutics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.